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Abstract
L-Tryptophan, technically pure, is a feed additive produced by fermentation with a genetically modiﬁed
strain of Escherichia coli. The Panel on Additives and Products or Substances used in Animal Feed
(FEEDAP) of EFSA, issued two opinions on the safety and efﬁcacy of the product, in which it could not
conclude on the safety of this additive for target animals, consumer, user and the environment, due to
the insufﬁcient characterisation of the genetic modiﬁcation. The European Commission asked the
Authority to deliver an opinion on the safety of L-tryptophan, technically pure, as a nutritional additive
for all animal species based on additional data submitted by the applicant. Based on new information
provided on the genetic modiﬁcation, including the presence/absence of antibiotic resistance genes in
the production strain, the FEEDAP Panel concludes that the L-tryptophan is safe for target animals,
consumers, users and the environment.
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
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Summary
Following a request from the European Commission (EC), the European Food Safety Authority
(EFSA) was asked to deliver a scientiﬁc opinion on the safety of L-tryptophan, technically pure,
produced by fermentation using the genetically modiﬁed strain Escherichia coli CGMCC 3667 for all
animal species.
In 2014, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) of the
EFSA adopted an opinion on the safety and efﬁcacy of L-tryptophan produced by fermentation using
E. coli CGMCC 3667. The FEEDAP Panel could not conclude on the safety of that product for target
animals, consumer, user and the environment because the genetic modiﬁcation, including the
presence/absence of recombinant DNA and of antibiotic resistance genes in the product, was
insufﬁciently characterised.
The applicant provided additional information in relation to the characterisation of the production
microorganism, the characterisation of the additive and its stability. The new information provided on
the genetic modiﬁcation was contradictory. Consequently, in another opinion of 2016, the FEEDAP
Panel could not conclude on the safety of the L-tryptophan produced by fermentation with this
recombinant strain of E. coli for target animals, consumers, users and the environment.
The applicant provided again additional information in relation to the characterisation of the
production microorganism. The FEEDAP Panel has performed the assessment of those new data
following an approach in line with the principles laid down in Regulation (EC) No 429/2008 and the
relevant guidance documents.
The genetic modiﬁcation is sufﬁciently characterised including the presence/absence of antibiotic
resistance genes in the production strain. Neither the production strain nor its recombinant DNA was
found in the ﬁnal product. Therefore, the FEEDAP Panel concludes that the product L-tryptophan,
produced by fermentation with E. coli CGMCC 3667, does not give raise to safety concerns for target
animals, consumers, users and the environment with respect to the genetic modiﬁcation of the
production strain.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1831/20031 establishes rules governing the Community authorisation of
additives for animal nutrition and, in particular, Article 9 deﬁnes the terms of the authorisation by the
Commission.
The applicant, GBT Europe GmbH, is seeking a Community authorisation of L-tryptophan,
technically pure, produced by fermentation with E. coli to be used as a nutritional additive for all
animal species (Table 1).
On 10 April 2014, the Panel on Additives and Products or Substances used in Animal Feed of the
European Food Safety Authority (“Authority”), in its opinion on the safety and efﬁcacy of the product
(EFSA FEEDAP Panel, 2014) could not conclude on the safety of the L-tryptophan produced by
fermentation with E. coli CGMCC 3667 for target animals, consumer, user and the environment.
Regardless of the assessment of the genetic modiﬁcation, the FEEDAP Panel had concerns on the use
of unprotected forms of L-tryptophan in ruminants, and on the safety of the amino acid L-tryptophan
for target species when administered simultaneously via water for drinking.
The Commission gave the possibility to the applicant to submit complementary information in order
to complete the assessment on the safety and to allow a revision of Authority’s opinion. The new
information provided on the genetic modiﬁcation was contradictory (EFSA FEEDAP Panel, 2016).
Consequently, the FEEDAP Panel could not conclude on the safety of the L-tryptophan produced by
fermentation with this recombinant strain of E. coli for target animals, consumers, users and the
environment. The Panel reiterated its concerns on the use of unprotected L-tryptophan to ruminants
and on the safety of the amino acid L-tryptophan for target species when administered simultaneously
via water for drinking.
The Commission gave another possibility to the applicant to submit complementary information in
order to complete the assessment on the safety and to allow a revision of Authority’s opinion. The
Commission has now received new data on the safety of L-tryptophan, technically pure, produced by
fermentation with E. coli CGMCC 3667.
In view of the above, the Commission asks the Authority to deliver a new opinion on the safety of
L-tryptophan, technically pure, produced by fermentation with E. coli as a nutritional additive for all
animal species based on the additional data submitted by the applicant.
1.2. Additional information
L-Tryptophan, technically pure (minimum content of L-tryptophan 98%, ‘as is’ basis), was ﬁrst
authorised for use in animal nutrition by Directive 88/485/EEC. It is currently included in the European
Union Register of Feed Additives pursuant to Regulation (EC) No 1831/2003 concerning additives in
feedingstuffs.
The applicant has submitted additional information on the characterisation of the production
microorganism.
Table 1: Description of the substances
Category of additive Nutritional additive
Functional group of additive amino acids, their salts and analogues
Description L-Tryptophan, technically pure, produced by fermentation with
Escherichia coli
Target animal category All animal species
Applicant GBT Europe GmbH
Type of request New opinion
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
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2. Data and methodologies
2.1. Data
The present assessment is based on the data submitted by the applicant in August 2016 in the
form of additional information2 to a previous application on the same product.3
2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the characterisation and safety of
L-tryptophan is in line with the principles laid down in Regulation (EC) No 429/20084 and the Guidance
on the risk assessment of genetically modiﬁed microorganisms and their products intended for food
and feed use (EFSA GMO Panel, 2011).
3. Assessment
The current application is for the authorisation of L-tryptophan, technically pure, produced by a
genetically modiﬁed (GM) strain of E. coli (CGMCC 3667). It is intended to be used in all animal
species as a nutritional additive to feed and water for drinking. The characterisation of the additive
and the description of the genetic modiﬁcation were assessed in previous opinions (EFSA FEEDAP
Panel, 2014, 2016). The genetic modiﬁcation, including the presence/absence of antibiotic resistance
genes in the production strain, was insufﬁciently characterised. Therefore, the present opinion focuses
on the new data provided by the applicant addressing this uncertainty.
3.1. Characterisation
3.1.1. Characterisation of the production organism
In the former assessment of the production strain (EFSA FEEDAP Panel, 2016), inconsistent
information was found regarding the presence of a gene conferring ampicillin resistance in plasmid
pEtrp, which is present in the production strain.
The applicant provided new Southern experiments5 investigating the presence or absence in the
production strain of all the antibiotic resistance genes used in the genetic modiﬁcation (ampicillin and
tetracycline remaining in plasmid pEtrp, chloramphenicol and apramycin used transiently). According to
the results, a positive signal was observed when genomic DNA from the production strain was
hybridised against a probe corresponding to the ampicillin resistance gene corresponding to the one
described in the genetic modiﬁcation. Furthermore, and in line with previous reports, the gene for
tetracycline resistance was also found present and the genes for chloramphenicol and apramycin
resistance were found absent. This is consistent with the description of the genetic modiﬁcation.
According to the new data provided, the production strain E. coli CGMCC 3667 carries genes for
ampicillin and tetracycline resistance located on the multicopy plasmid pEtrp. The absence in the ﬁnal
product of the production strain and of the whole ampicillin (861 bp) and tetracycline (1,191 bp)
resistance genes, which was previously shown (EFSA FEEDAP Panel, 2016), was conﬁrmed with new
experiments.6,7
3.2. Safety
The traits introduced in the production strain E. coli CGMCC 3667 include tetracycline and ampicillin
resistance, conferred by recombinant genes located together on a multicopy plasmid. Neither the
production strain nor its recombinant DNA were found in the ﬁnal product. Therefore, the product
L-tryptophan, produced by fermentation with E. coli CGMCC 3667, does not give raise to safety
2 Dossier reference: FAD-2016-0047.
3 Dossier reference: FAD-2010-0290.
4 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
5 Technical dossier/Annex 3.
6 Technical dossier/Annex 2.
7 Technical dossier/Annex 1.
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concerns for target animals, consumers, users and the environment with respect to the genetic
modiﬁcation of the production strain.
4. Conclusions
Neither the production strain nor its recombinant DNA was found in the ﬁnal product. Therefore,
the product L-tryptophan, produced by fermentation with E. coli CGMCC 3667, does not give raise to
safety concerns for target animals, consumers, users and the environment with respect to the genetic
modiﬁcation of the production strain.
Documentation provided to EFSA
1) L-Tryptophan technically pure produced by fermentation with E. coli. Supplementary
information. August 2016. Submitted by Global Bio-Chem (GBT Europe GmbH).
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Abbreviations
CGMCC China General Microbiological Culture Collection Center
FEEDAP EFSA Panel on Additives and Products or Substances used in Animal Feed
GM genetically modiﬁed
GMO genetically modiﬁed organism
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